Steven Coutre
Academic Appointments
- Professor - Med Center Line, Medicine - Hematology
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Hematology Clinic 875 Blake Wilbur Dr Clinic C MC 5820 Stanford, CA 94305 Tel Work (650) 498-6000 Fax (650) 724-5203
- Academic Offices
Personal Information EmailAlternate Contact Jillian Settlemire RN Email Tel Work 650 498 6000Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Hematology
- Cancer> Hematology> Leukemia - Acute and Chronic
- Hematology
- Leukemia
- Chronic Lymphocytic Leukemia
- Multiple Myeloma
Administrative Appointments
- Vice Chair, Clinical Affairs, Department of Medicine (2011 - present)
- Disease Management Group Leader-Hematology, Stanford Hospital and Clinics (2010 - present)
- Acute Myeloid Leukemia Panel, National Comprehensive Cancer Network (1998 - present)
- Acute Lymphoblastic Leukemia Panel, National Comprehensive Cancer Network (2012 - present)
- Vice Chair, Leukemia Committee, Southwest Oncology Group (1996 - present)
- Director of Hematology Clinic, Stanford University (1996 - present)
Honors and Awards
- Timothy F. Beckett, Jr. Award for Excellence in Clinical Teaching, Stanford University (1990)
- Bernard Cohen Postdoctoral Fellowship, Stanford University (1991)
- Division Teaching Award, Stanford University (2002)
Professional Education
| Fellowship: | Stanford University School of Medicine CA (1992) |
| Residency: | Yale - New Haven Hospital CT (1989) |
| Internship: | Yale - New Haven Hospital CT (1987) |
| Medical Education: | Stanford University School of Medicine CA (1986) |
| BS: | Northwestern University, Biochemistry (1981) |
| MD: | Stanford University, Medicine (1986) |
Graduate & Fellowship Program Affiliations
Internet Links
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
My work emphasizes both patient care and translational research. I focus on both the hematologic malignancies as well as conditions such as anemia and blood clotting disorders. Our program offers novel treatments for many of these conditions in the context of clinical trials. We also have comprehensive laboratory services offering the most up-to-date testing for both the diagnosis and management of complex hematologic problems. Recent clinical protocols involved the treatment of acute myeloid leukemia, acute lymphoid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, multiple myeloma, prolymphocytic leukemia, hypereosinophilic syndrome, systemic mastocytosis and heparin-induced thrombocytopenia.
Clinical Trials
- Not Recruiting To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.
- Not Recruiting Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
- Recruiting A Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2)
- Recruiting An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil)
- Recruiting An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Publications
- Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol. 2012; (11): 1096-104
- Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012; (15): 1822-8
- Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010; (19): 3751-7
- Optimizing therapy for acute myeloid leukemia. J Natl Compr Canc Netw. 2008; (10): 1003-16
- Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007; (8): 3207-13
- Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007; (7): 2309-15
Help
Trial Administration